Navigation Links
BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
Date:5/11/2009

llagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for commercialization of XIAFLEX(TM) in Europe and other territories.

More information about the Company may be found on its website at www.biospecifics.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, our expected revenue growth, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including the ability of our partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments we may receive; the amount of earn out payments we may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under our license agreement for additional indications; the pote
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
2. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
3. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
5. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
6. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
7. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
8. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
9. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
10. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
11. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 24, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... that it will hold its 2015 Annual Meeting of ... Because the expected date for the Annual Meeting ...
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... 2014 Pipette.com announces their Holiday ... can submit their #HolidayInTheLab pictures for a chance to ... , For those struggling to think of a holiday ... in the Lab Contest provides the ideal holiday presents. ... to send pictures of their chemistree, holiday sweaters, as ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... and Grocery Delivery Service Initiates ... Biodiesel Use in Delivery Fleet, LONG ISLAND CITY, ... food purveyors and delivery services, today,announced that it has signed a ... early January of 2008,FreshDirect,s fleet of 150 delivery trucks will start ...
... 17 In its second annual young,investigators special issue, ... are making an impact early in their careers. The ... through the,eyes of some of the best and brightest ... areas of interest., The young investigators were nominated ...
... Ph.D., continues as Chief Technology Officer, MENLO ... development stage company commercializing a patented,proprietary sensor technology ... and consumer markets announced today that Robin C.,Stracey ... Executive Officer,effective December 17, 2007. He has also ...
Cached Biology Technology:FreshDirect's Fleet Goes Biodiesel 2FreshDirect's Fleet Goes Biodiesel 3Genome Technology Magazine Names Top Young Investigators of 2007 2Robin C. Stracey Joins Cantimer, Inc. as President and CEO 2
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Nature Medicine describes how different types of immune system ... bone and tissue, bringing into sharp focus the importance ... regeneration. The study, conducted at the Center for ... of USC, examined how mice with genetic bone defects ...
... it appears as a speck of blood in the sky, the ... the point of view of life as we know it, that,s ... Planet,s thin atmosphere does little to shield the ground against radiation ... the soil. Liquid water, a necessity for life, can,t exist for ...
... This press release is available in German ... are built up from only twenty amino acids. 25 years ... years ago a 22nd, the pyrrolysine. However, how the cell ... at the Technische Universitaet Muenchen have elucidated the structure of ...
Cached Biology News:New NASA missions to investigate how Mars turned hostile 2New NASA missions to investigate how Mars turned hostile 3New NASA missions to investigate how Mars turned hostile 4Enzymatic synthesis of pyrrolysine, the mysterious 22nd amino acid 2Enzymatic synthesis of pyrrolysine, the mysterious 22nd amino acid 3
Co-precipitant is free of background polynucleotides,Dnases,Rnases, proteases. 20mg/ml...
... monitoring Aldolase tests. 2 levels of ... manufacturing values at 4 ± 2 ... 30-day shelf life once opened ... 1: 3 x 3 ml; Level ...
Human VEGF-D Biotinylated MAb (Clone 78923)...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: